Clinical Trials Directory

Trials / Unknown

UnknownNCT06206382

Surgical Results of Resection of Locally Advanced Pancreatic Cancer

Surgical Outcome of Borderline Resectable Pancreatic Cancer: Upfront Surgery Versus Neoadjuvant Chemotherapy (Single Center Experience)

Status
Unknown
Phase
Study type
Observational
Enrollment
80 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
20 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The aim is to compare the surgical outcomes between upfront surgery and surgery after neoadjuvant chemotherapy in terms of morbidity and mortality

Detailed description

Pancreatic cancer is the fourth leading cause of cancer death in the United States. While surgical resection remains the only curative option, more than 80% of patients present with unresectable disease. Unfortunately, even among those who undergo resection, the reported median survival is 15-23 mo, with a 5-year survival of approximately 20%. Disappointingly, over the past several decades, despite improvements in diagnostic imaging, surgical technique and chemotherapeutic options, only modest improvements in survival have been realized. Nevertheless, it remains clear that surgical resection is a prerequisite for achieving long-term survival and cure. The concept of borderline resectable pancreatic cancer has evolved from several clinical observations made over decades. It has been recognized for some time that the prognosis for patients undergoing surgical resection for pancreatic ductal adenocarcinoma (PDAC) is highly dependent on margin status, with total gross excision and histologically negative margins (R0 resection) being associated with the best outcomes. Survival for patients who undergo total gross excision but have histologically positive margins (R1 resection) have a reduced survival in most series

Conditions

Interventions

TypeNameDescription
PROCEDUREWhipple operationWhipple operation is the surgery used for pancreatic head cancer in the form of pancreaticoduodenectomy then reconstruction

Timeline

Start date
2024-01-05
Primary completion
2025-09-01
Completion
2025-10-01
First posted
2024-01-16
Last updated
2024-01-16

Source: ClinicalTrials.gov record NCT06206382. Inclusion in this directory is not an endorsement.